HKSE · 1801.HK
Innovent Biologics, Inc.
HK$81.65+HK$0.05 (+0.06%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.55% below the high.
Loading market information…
HKSE · 9887.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:58 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Nanjing Leads Biolabs Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 62.26% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nanjing Leads Biolabs Co Ltd’s next earnings report is currently expected on Mar 29, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nanjing Leads Biolabs Co Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$81.65+HK$0.05 (+0.06%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.55% below the high.
HK$49.68-HK$0.24 (-0.48%)
Shanghai Henlius Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.96% below the high.
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$9.91+HK$0.06 (+0.61%)
HBM Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 41.97% below the high.
HK$5.05+HK$0.31 (+6.55%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 51.54% below the high.
HK$6.34-HK$0.15 (-2.31%)
Alphamab Oncology’s quoted price sits in the lower half of its reported 52-week range, 48.03% below the high.
HK$3.21+HK$0.14 (+4.57%)
Lepu Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 53.42% below the high.
HK$26.10-HK$0.34 (-1.29%)
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 22.78% below the high.
